Middleton & Co Inc MA Buys 11,315 Shares of Johnson & Johnson (JNJ)
Middleton & Co Inc MA increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 40.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,272 shares of the company’s stock after buying an additional 11,315 shares during the quarter. Middleton & Co Inc MA’s holdings in Johnson & Johnson were worth $5,106,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Harding Loevner LP acquired a new position in Johnson & Johnson during the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. IHT Wealth Management LLC boosted its position in Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson during the 2nd quarter worth $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new position in Johnson & Johnson during the 2nd quarter worth $177,000. Hedge funds and other institutional investors own 65.72% of the company’s stock.
Shares of Johnson & Johnson (JNJ) opened at $147.36 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $395,885.59, a price-to-earnings ratio of 25.58, a PEG ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $148.32.
A number of brokerages have issued reports on JNJ. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price target for the company. in a research report on Friday, October 13th. Stifel Nicolaus boosted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. Wells Fargo & Co upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $140.00 to $149.00 in a research report on Monday, October 9th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $145.94.
ILLEGAL ACTIVITY WARNING: “Middleton & Co Inc MA Buys 11,315 Shares of Johnson & Johnson (JNJ)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/01/22/middleton-co-inc-ma-buys-11315-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.